NHS England has declared a pause on new dispensing of cross-sex hormones for teenagers aged 16-17 exploring gender identity questions, in the wake of a thorough examination that found earlier studies into the drugs’ safety and effectiveness was insufficient. The decision, which comes into force right away, comes after an independent evidence review commissioned by the health service concluded there was inadequate quality evidence to establish whether the hormones benefit or harm teenagers. Teenagers currently on the treatment will continue their prescriptions, though clinicians will be required to assess their cases. NHS England said a limited number of young people would be affected by the pause and will be provided with other treatment options at three gender clinics operated by the NHS for children serving England.
The Choice and Its Reach
The pause reflects a notable transition in NHS England’s strategy for gender-affirming medical care for young people. Cross-sex hormones, which assist those acquire bodily features connected to their chosen gender, can cause irreversible changes including a more masculine voice, breast growth, or other lasting changes. The decision to halt new prescribing stems from the NHS’s assessment that existing evidence cannot clearly demonstrate whether these therapies benefit or damage adolescents dealing with gender-related distress. Professor James Palmer, National Medical Director for Specialised Services at NHS England, highlighted that the review had been “extremely thorough and intricate,” finally concluding that existing evidence does not justify continued use of masculinising or feminising hormones for those under 18.
NHS England has started a 90-day public consultation starting Monday to collect additional feedback on the revised policy and review findings. The NHS hopes this consultation period will identify any evidence that could have been missed during the initial review process. Existing guidance already banned prescriptions for under-16s requesting gender-related treatment, so the new pause essentially broadens restrictions to cover 16 and 17-year-olds. The NHS stressed its dedication to offering full support, stating that young people unable to access hormone therapy will be offered alternative forms of care through its three specialized gender clinics for children across England.
- Pause covers new prescriptions for adolescents aged 16-17 only
- Young people already on hormones will maintain existing treatment
- Clinicians will assess existing cases for ongoing suitability
- Alternative care provided at three NHS gender clinics nationally
Review of Evidence Findings
The choice to suspend hormone prescriptions stems directly from a thorough evidence assessment commissioned by NHS England, which assessed the scientific basis for cross-sex hormone treatment in adolescents. The assessment, consisting of ten independent assessments of different aspects of testosterone and oestrogen use, uncovered notable deficiencies in the evidence supporting existing clinical practice. NHS England determined that the available evidence was inadequate to establish whether these treatments help or harm young people with gender dysphoria, making it impossible to justify continuing new prescriptions with confidence in their safety and efficacy.
This observation reflects issues highlighted in Dr Hilary Cass’s significant April 2024 report on gender care for children, which noted “remarkably weak” evidence surrounding therapeutic approaches in this field. The Cass assessment prompted NHS England to perform its own thorough examination of the research foundation. The subsequent assessment examined various outcomes for young patients, such as wellbeing quality, mental health, and overall health. Rather than delaying for additional evidence to develop, NHS England chose to implement a precautionary approach, suspending new prescriptions while proceeding to evaluate responses from advocacy groups and healthcare professionals.
What the Research Showed
The ten independent evidence assessments examined the impact of masculinising and feminising hormones across a range of health and psychological outcomes for adolescents with a gender identity different from their sex at birth. Researchers assessed published studies on how these treatments impacted quality of life, mental health status, and gender-related distress in young people. The review was intentionally thorough, seeking to leave no stone unturned in assessing whether sufficient evidence existed to support ongoing prescription for under-18s.
The overarching conclusion was clear: the body of evidence did not reach the threshold necessary to confidently recommend hormone treatment for this demographic. Professor Palmer stated that the review “demonstrated that the body of evidence does not justify the sustained use of hormone treatments” to treat young people under 18 with gender dysphoria. This result meant NHS England could not definitively determine whether the treatments were beneficial or detrimental, necessitating a halt subject to further clarification and expert review.
- Ten distinct analyses examined different aspects of endocrine treatment
- Studies evaluated wellbeing and psychological results
- Body of evidence found limited to warrant ongoing treatment
- Cannot determine if therapies harm or help youth
Reactions and Court Disputes
The NHS decision to pause hormone prescriptions has triggered swift and polarised responses from across the health and campaigning sectors. Trans advocacy groups have expressed strong opposition to the policy shift, with some organisations indicating their plans to pursue legal action against NHS England. These groups contend that the pause limits availability to potentially life-changing treatment for adolescents with gender dysphoria, and maintain that the evidence assessment does not justify such a restrictive approach. The consultation period starting Monday will be vital in establishing whether NHS England’s position shifts or strengthens based on stakeholder feedback.
Healthcare practitioners working in gender identity services have also commented on the decision, with views extending across cautious support to major worries. Some clinicians endorse the evidence evaluation as a necessary step to confirm treatments are adequately supported, while others worry that the pause may negatively affect vulnerable young people who have already begun hormone therapy or are seeking to obtain care. The 90-day consultation period represents an opportunity for these varied perspectives to formally present their perspectives, conceivably shaping whether the temporary pause transforms into permanent policy or is revised based on new evidence or professional consensus.
| Group | Position |
|---|---|
| Trans Advocacy Organisations | Opposing the pause; considering legal action against NHS England |
| Some Healthcare Professionals | Supporting cautious approach; welcoming evidence-based review |
| Other Clinicians | Concerned about harm to young people already in treatment |
| NHS England Leadership | Defending precautionary approach; seeking further consultation |
Advocacy Organization’s Response
Trans advocacy organisations have condemned the NHS pause as unfairly restrictive and potentially harmful to young people in vulnerable situations. These groups maintain that the choice to stop additional prescriptions contradicts the experiences of transgender adolescents who report improved mental health and life quality following hormone treatment. They assert that the review’s findings of “weak evidence” does not justify such a restrictive policy, and that the pause effectively denies care to individuals requiring it most while pending complete scientific confirmation that might never emerge.
Legal challenges are expected, with activist groups indicating they will explore court action to challenge or alter the prescription pause. These groups maintain that the policy violates the rights of youth to receive suitable healthcare and might represent bias against gender identification. They emphasise that individual clinical assessments must guide treatment access as opposed to across-the-board bans, and that the discussion phase needs to thoroughly review testimony from transgender communities themselves about personal experiences with hormone-based treatment.
Commercial Sector and Global Framework
While NHS England adopts its measured approach, the private medical industry in the United Kingdom keeps providing hormone treatments to adolescents outside the NHS framework. This creates a stratified healthcare model where affluent households may access treatments that the NHS has put on hold, raising concerns about fairness and availability. The gap between NHS policy and private healthcare delivery highlights fundamental issues about how research-backed standards should apply across diverse care contexts, and whether young people’s access to gender-affirming care should rest on their family’s financial resources rather than clinical requirement.
Internationally, healthcare systems have implemented varying approaches to hormone treatment for young people questioning their gender. Some European countries, including Sweden and Finland, have likewise restricted restrictions on cross-sex hormones for minors in the past several years, citing insufficient evidence. Conversely, other nations maintain more permissive treatment guidelines, with some medical organisations contending that withholding care causes greater psychological harm. These differing global approaches underscore the genuine scientific uncertainty surrounding the lasting impacts and advantages of these interventions, and suggest that no consensus yet exists among global medical authorities on the suitable course of treatment for young people experiencing gender dysphoria.
- Private clinics in the UK continue to offer hormonal therapy to young people in spite of NHS pause
- Sweden and Finland have equally curbed hormonal medications for minors in the past few years
- International medical organisations remain divided on proper treatment guidelines for adolescents
What’s Next
NHS England has launched a structured process to establish its future direction on gender-affirming care for teenagers questioning their gender. A three-month public engagement commenced on Monday will gather feedback from patient representatives, clinical experts, and the wider public on the evidence review findings and proposed revised guidance. The health service has stressed that this engagement process is essential for uncovering any evidence that may have been overlooked during the original assessment. The outcomes will influence whether the current pause on fresh prescriptions becomes enduring practice or whether treatment restarts under adjusted guidelines.
During the consultation period, NHS England will maintain oversight of young people already receiving hormone treatment, with clinicians conducting individualised reviews of each patient’s care pathway. The three established NHS gender clinics for children will expand their provision of other forms of support for those unable to access hormones, including psychological support and counselling services. Upon completion of the 90-day period, NHS England will assess all input received and reach a final determination regarding longer-term guidance. This decision will have major consequences for numerous young people across England seeking gender-affirming medical interventions.
The 90-Day Consultation Procedure
The consultation represents a formal opportunity for stakeholders to challenge or support NHS England’s preliminary findings. Advocacy groups, medical professionals, and members of the general public can provide evidence and viewpoints on whether the review properly captures existing scientific knowledge. Trans advocacy organisations have already indicated they may pursue legal action, suggesting the consultation will be contentious. NHS England has indicated it will genuinely consider all responses, specifically aiming to find any robust evidence that the initial review may have missed or underweighted in its analysis.
The 90-day timeframe is designed to reconcile the requirement for comprehensive consideration with the urgency of delivering transparency to youth and medical professionals currently uncertain about treatment availability. NHS England will gather and analyse all feedback received before releasing its final decision on updated guidance. This additional time permits healthcare professionals to express practical experience, research institutions to submit further data, and youth in their own right to explain how the new policies affect their wellbeing and quality of life.
